Zanubrutinib with chemotherapy before stem cell transplant for lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug (zanubrutinib) combined with a strong chemotherapy regimen (BEAM) before a stem cell transplant. The goal is to see if this combination can help people whose lymphoma has come back or not responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to at least two prior treatments.
- Your cancer should have shrunk or disappeared after your last treatment (partial or complete response).
- You cannot have had a stem cell transplant using your own cells before.
- Your heart, liver, and kidneys must be working well enough, and your blood counts must be within a certain range.
- You must be able to take care of yourself (ECOG score 0-2) and live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a targeted drug called pirtobrutinib to a standard high-dose chemotherapy regimen before a stem cell transplant. It aims to improve outcomes for people with diffuse large B-cell lymphoma that has come back or not responded to previous treatments.
This trial tests adding the drug selinexor to a standard high-dose chemotherapy regimen (BEAM) before an autologous stem cell transplant for people with MYC-positive diffuse large B-cell lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination is safe and effective in preparing the body for the transplant.
This trial tests a new drug called zanubrutinib combined with standard chemotherapy for people newly diagnosed with a type of brain lymphoma. The goal is to see if this combination works better than chemotherapy alone.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.